Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Shared Mechanisms Contributing to Non-Alcoholic Fatty Liver Disease (NAFLD) and Psoriatic Disease (PD) Severity With Guselkumab Therapy [EMERGE]

NCT07255781 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT07255781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07255781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Shared Mechanisms Contributing to Non-Alcoholic Fatty Liver Disease (NAFLD) and Psoriatic Disease (PD) Severity With Guselkumab Therapy [EMERGE]
Lead sponsor
University of California, San Diego
Phase
Observational
Overall status
Withdrawn
Start date
November 30, 2025
Completion date
November 30, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nafld (nonalcoholic fatty liver disease), psa (psoriatic arthritis), psoriasis (pso)